结缔组织增生
医学
基质
癌症
癌症研究
间质细胞
胰腺癌
癌相关成纤维细胞
间充质干细胞
黑色素瘤
肿瘤微环境
肺癌
乳腺癌
癌变
肿瘤科
作者
Upasana Ray,Christopher L Pathoulas,Prabhu Thirusangu,James W Purcell,Nagarajan Kannan,Viji Shridhar
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2022-05-03
卷期号:82 (9): 1675-1681
标识
DOI:10.1158/0008-5472.can-21-3734
摘要
Abundant fibrotic stroma is a typical feature of most solid tumors, and stromal activation promotes oncogenesis, therapy resistance, and metastatic dissemination of cancer cells. Therefore, targeting the tumor stroma in combination with standard-of-care therapies has become a promising therapeutic strategy in recent years. The leucine-rich repeat-containing protein 15 (LRRC15) is involved in cell-cell and cell-matrix interactions and came into focus as a promising anticancer target owing to its overexpression in mesenchymal-derived tumors such as sarcoma, glioblastoma, and melanoma and in cancer-associated fibroblasts in the microenvironment of breast, head and neck, lung, and pancreatic tumors. Effective targeting of LRRC15 using specific antibody-drug conjugates (ADC) has the potential to improve the outcome of patients with LRRC15-positive (LRRC15+) cancers of mesenchymal origin or stromal desmoplasia. Moreover, LRRC15 expression may serve as a predictive biomarker that could be utilized in the preclinical assessment of cancer patients to support personalized clinical outcomes. This review focuses on the role of LRRC15 in cancer, including clinical trials involving LRRC15-targeted therapies, such as the ABBV-085 ADC for patients with LRRC15+ tumors. This review spans perceived knowledge gaps and highlights the clinical avenues that need to be explored to provide better therapeutic outcomes in patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI